Decoy Therapeutics Inc. 10-K — AI Bull & Bear Analysis

The 10-K reveals a company at a critical crossroads, balancing a sophisticated technological leap against an existential financial struggle. The integration of the IMP³ACT platform and the shift toward pan-coronavirus therapeutics provide a clear, high-upside vision, but the balance sheet remains the primary headwind. The company has successfully navigated immediate Nasdaq delisting threats through reverse splits and compliance plans, yet the underlying need for substantial capital to reach the 2027 IND filing remains acute. Investors are essentially betting on a binary outcome: whether the AI-accelerated pipeline can produce a proof-of-concept success in human trials before the cash runway expires in late 2026. While the non-dilutive grant support provides a temporary cushion, the lack of revenue and the high cost of clinical scaling create a high-risk environment. The overall impact of the filing is a transition from a legacy small-molecule entity to a platform-based biotech, but one that is currently operating on a razor-thin margin of survival.